The need to develop anti-
influenza drugs with novel
antiviral mechanisms is urgent because of the rapid rate of antigenic mutation and the emergence of drug-resistant viruses. We identified a novel anti-
influenza molecule by screening 861 plant-derived natural components using a high-throughput image-based assay that measures inhibition of the influenza virus
infection. 1,3,4,6-tetra-O-galloyl-β-D-glucopyranoside (
TGBG) from Euphorbia humifusa Willd showed broad-spectrum anti-
influenza activity against two seasonal
influenza A strains, A/California/07/2009 (H1N1) and A/Perth/16/2009 (H3N2), and seasonal
influenza B strain B/Florida/04/2006. We investigated the mode of action of
TGBG using
neuraminidase activity inhibition and time-of-addition assays, which evaluate the viral release and entry steps, respectively. We found that
TGBG exhibits a novel
antiviral mechanism that differs from the FDA-approved anti-
influenza drugs
oseltamivir which inhibits viral release, and
amantadine which inhibits viral entry. Immunofluorescence assay demonstrated that
TGBG significantly inhibits nuclear export of
influenza nucleoproteins (NP) during the early stages of
infection causing NP to accumulate in the nucleus. In addition,
influenza-induced activation of the Akt signaling pathway was suppressed by
TGBG in a dose-dependent manner. These data suggest that a putative mode of action of
TGBG involves inhibition of viral
ribonucleoprotein (vRNP) export from the nucleus to the cytoplasm consequently disrupting the assembly of progeny virions. In summary,
TGBG has potential as novel anti-
influenza therapeutic with a novel mechanism of action.